Budesonide/mesalazine suppository - Dr. Falk Pharma

Drug Profile

Budesonide/mesalazine suppository - Dr. Falk Pharma

Alternative Names: mesalazine/budesonide suppository

Latest Information Update: 24 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dr Falk Pharma
  • Class Aminosalicylic acids; Anti-inflammatories; Antiallergics; Glucocorticoids; Irritable bowel syndrome therapies; Pregnenediones; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists; Lipoxygenase-cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Ulcerative proctitis

Most Recent Events

  • 24 Feb 2016 No recent reports on development identified - Phase-II for Ulcerative proctitis in Germany (Rectal)
  • 01 Aug 2015 Dr. Falk Pharma completes a phase II trial in Ulcerative proctitis in Germany (Rectal) (NCT01966783)
  • 01 Sep 2013 Phase-II clinical trials in Ulcerative proctitis in Germany (Rectal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top